ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,084.61
-0.26%
Dow Jones
42,840.26
1.18%
Gold vs US Dollar
2,623.175
0.00%
Brent Oil
72.72
0.00%
Bitcoin
98,441.08
0.70%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lantern Pharma Inc (LTRN) Share Price

LTRN Lantern Pharma Inc

3.25
0.073 (2.30%)
21 Dec 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Lantern Pharma Inc NASDAQ:LTRN NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.073 2.30 3.25 2.80 4.25 3.41 3.10 3.17 39,336 05:00:01   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -15.96M -1.4801 -2.11 34.26M
 Type  Size  Price  Time  Units 
 20 100 3.25 23:53:24 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore LTRN News
09/12/202413:15BWLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
03/12/202413:00BWLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
26/11/202413:45BWLantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
19/11/202413:00BWLantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
07/11/202421:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202421:05EDGAR2Form 8-K - Current report
07/11/202421:05BWLantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
Period
Draw mode
Data Downloads for LTRN

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Lantern Pharma Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads